Compare Stocks: INVVY, PHAT, ARCT, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$15.49 +0.3%	$7.40	$5.50 ▼ $24.17	$442.24M	2.39	568,340 shs	1.33 million shs
INVVY Indivior	$21.85 -1.8%	$21.85	$14.76 ▼ $35.50	$3.01B	0.35	3,825 shs	8,100 shs
PHAT Phathom Pharmaceuticals	$8.78 -0.3%	$10.31	$8.21 ▼ $18.31	$710.30M	0.51	1.24 million shs	376,070 shs
RYTM Rhythm Pharmaceuticals	$112.47 -0.8%	$108.94	$74.50 ▼ $122.20	$7.69B	1.92	772,862 shs	102,327 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+7.67%	+88.06%	+179.20%	+101.57%	-12.82%
INVVY Indivior	0.00%	0.00%	0.00%	0.00%	0.00%
PHAT Phathom Pharmaceuticals	+1.62%	-4.86%	-23.08%	-18.06%	-23.94%
RYTM Rhythm Pharmaceuticals	+1.71%	-1.65%	+11.02%	+23.99%	+14.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$15.49 +0.3%	$7.40	$5.50 ▼ $24.17	$442.24M	2.39	568,340 shs	1.33 million shs
INVVY Indivior	$21.85 -1.8%	$21.85	$14.76 ▼ $35.50	$3.01B	0.35	3,825 shs	8,100 shs
PHAT Phathom Pharmaceuticals	$8.78 -0.3%	$10.31	$8.21 ▼ $18.31	$710.30M	0.51	1.24 million shs	376,070 shs
RYTM Rhythm Pharmaceuticals	$112.47 -0.8%	$108.94	$74.50 ▼ $122.20	$7.69B	1.92	772,862 shs	102,327 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	+7.67%	+88.06%	+179.20%	+101.57%	-12.82%
INVVY Indivior	0.00%	0.00%	0.00%	0.00%	0.00%
PHAT Phathom Pharmaceuticals	+1.62%	-4.86%	-23.08%	-18.06%	-23.94%
RYTM Rhythm Pharmaceuticals	+1.71%	-1.65%	+11.02%	+23.99%	+14.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$20.00	29.13% Upside
INVVY Indivior	3.00	Buy	$50.00	128.88% Upside
PHAT Phathom Pharmaceuticals	2.88	Moderate Buy	$22.86	160.48% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$142.44	26.64% Upside

Current Analyst Ratings Breakdown

Latest INVVY, PHAT, ARCT, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	RYTM Rhythm Pharmaceuticals	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$160.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$142.00 ➝ $143.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$141.00 ➝ $155.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$155.00 ➝ $160.00
7/31/2026	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/31/2026	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00 ➝ $22.00
7/31/2026	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	5.37	N/A	N/A	$6.04 per share	2.56
INVVY Indivior	$791M	3.81	$1.15 per share	18.94	$1.45 per share	15.07
PHAT Phathom Pharmaceuticals	$175.11M	4.05	N/A	N/A	($4.26) per share	-2.06
RYTM Rhythm Pharmaceuticals	$189.76M	40.62	N/A	N/A	$1.50 per share	74.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
INVVY Indivior	$205M	$1.05	20.81	12.00	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	7.56	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest INVVY, PHAT, ARCT, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
INVVY Indivior	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
INVVY Indivior	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
INVVY Indivior	0.05%
PHAT Phathom Pharmaceuticals	99.01%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
INVVY Indivior	N/A
PHAT Phathom Pharmaceuticals	9.33%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
INVVY Indivior	800	137.88 million	N/A	Not Optionable
PHAT Phathom Pharmaceuticals	110	80.90 million	73.35 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable

INVVY, PHAT, ARCT, and RYTM Headlines

Recent News About These Companies

Primecap Management Co. CA Invests $351.84 Million in Rhythm Pharmaceuticals, Inc. $RYTM

August 26 at 6:08 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Acquires New Stake in Rhythm Pharmaceuticals, Inc. $RYTM

August 26 at 4:15 AM | marketbeat.com

Algert Global LLC Grows Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 26 at 3:04 AM | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM

August 26 at 3:03 AM | marketbeat.com

Nicholas Investment Partners LP Makes New $15.46 Million Investment in Rhythm Pharmaceuticals, Inc. $RYTM

August 25 at 6:32 AM | marketbeat.com

Nan Fung Group Holdings Ltd Purchases New Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 25 at 5:51 AM | marketbeat.com

Rhythm Pharmaceuticals Receives Japan Approval for Imcivree

August 24 at 6:11 PM | finance.yahoo.com

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

August 24 at 8:00 AM | globenewswire.com

6,156,902 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by BlackRock Inc.

August 24 at 3:35 AM | marketbeat.com

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

August 23 at 6:00 PM | fool.com

Deutsche Bank AG Purchases New Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 23 at 3:43 AM | marketbeat.com

Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM

August 21, 2026 | marketbeat.com

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

August 18, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Joseph Shulman Sells 5,079 Shares

August 18, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock

August 17, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares

August 17, 2026 | marketbeat.com

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

August 17, 2026 | globenewswire.com

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts

August 17, 2026 | marketbeat.com

Jennifer Kayden Lee Sells 75,834 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

August 16, 2026 | americanbankingnews.com

Yann Mazabraud Sells 57,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

August 16, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares of Stock

August 15, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVVY, PHAT, ARCT, and RYTM Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$15.49 +0.05 (+0.31%)

As of 12:53 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Indivior OTCMKTS:INVVY

$21.85 -0.40 (-1.82%)

As of 06/9/2023

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.

Phathom Pharmaceuticals NASDAQ:PHAT

$8.78 -0.03 (-0.28%)

As of 12:53 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$112.47 -0.88 (-0.78%)

As of 12:52 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INVVY, PHAT, ARCT, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INVVY, PHAT, ARCT, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INVVY, PHAT, ARCT, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVVY, PHAT, ARCT, and RYTM Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Indivior OTCMKTS:INVVY

Phathom Pharmaceuticals NASDAQ:PHAT

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INVVY, PHAT, ARCT, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INVVY, PHAT, ARCT, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INVVY, PHAT, ARCT, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVVY, PHAT, ARCT, and RYTM Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

Indivior OTCMKTS:INVVY

Phathom Pharmaceuticals NASDAQ:PHAT

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools